Share on Facebook
Share on Twitter
Share on LinkedIn

Like the others in the clinical trial, Patient No. 11561004 already had tried one treatment for his advanced kidney cancer, but it didn’t work.

So the 69-year-old man volunteered to try an unproven drug that offered some hope he might live longer.

Less than four months after going on the drug known as Inlyta, the man — identified only by age and a number in an FDA review of the clinical trial— developed severe abdominal pain, was admitted to the hospital and died that day from gastrointestinal bleeding.

Read more.